anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE: To obtain a dermal preparation for external use, excellent in humectant properties and having high antioxidant properties and high safety. CONSTITUTION: This dermal preparation for external use contains an extract of a cow&#39;s milk fatty globular film and/or its treated substance as an active ingredient in an amount of 0.05-10wt.% therein. Cow&#39;s milk or a dairy product containing the cow&#39;s milk fatty globular film can directly be used as the cow&#39;s milk fatty globular film or a film, separated and produced therefrom can be used as the cow&#39;s milk fatty globular film and whole fat milk, a buttermilk, butter serum, whey protein concentrate, etc., can suitably be used. The extract is prepared by extraction with a mixed solvent of a lower alcohol with water and/or further a low polar and water-immiscible solvent (e.g. hexane). In the process, the solvents are used at (97:3) to (70:30) mixing ratio of the lower alcohol to water and (90:10) to (50:50) mixing ratio of the mixed solvent to the low polar solvent.  A concentrate, a pasty substance, a dried substance and/or a diluted substance of the extract are used as the treated substance and a polar lipid, minerals, a nonprotein nitrogen compound, vitamin E, etc., are further blended therein.
A method of detecting residual liquid perm on hair uses green paper normally used as a hand towel which involves placing the green paper in contact with a liquid suspected of containing liquid perm and monitoring the change in colour. Suitable green papers are those marketed as e.g. KiMDRi (RTM), HiDRi (RTM) etc. and they are particularly in the form of hand towels. Also disclosed is a liquid perm detector presentation arrangement comprising a stock of green paper sheets of the hand towel type dispensable on demand to the hairdresser. &lt;IMAGE&gt;
PURPOSE:To provide the subject low irritant and low toxic absorption accelerating agent containing a specific polyorganosiloxane and having a good percutaneous absorption-accelerating activity for medicines. CONSTITUTION:The objective absorption-accelerating agent contains a polyorganosiloxane having a carboxylic acid residue at one molecular end and represented by formula I (R&lt;1&gt;-R&lt;5&gt; are 1-6C alkyl, phenyl; A is 2-13C divalent alkylene or divalent alkylene bonded to a methylenephenylene; n is 1 or larger) or formula II (M is alkali metal). The compound of formula I is obtained e.g. by reacting a polyorganosiloxane having a halomethylphenyl group at one molecular end and represented by formula III with water and carbon monoxide in the presence of a group VIII transition metal element and a base. The compound of formula II is also obtained by reacting the compound of formula I with an alkali metal hydroxide. The absorption-accelerating agent is dissolved together with a medicine to be administered in a solvent such as water or an alcohol and subsequently added to a tinctura, an ointment, etc.
PURPOSE: A composition for treating or preventing colitis including the saponin is provided to control IL-1 beta, IL-6, and expression of tumor necrosis factor alpha, thereby effective for colitis treatment. CONSTITUTION: A composition for treating or preventing colitis comprises lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as an active ingredient. The saponin is isolated from Condonopsis lanceolata Trautv fermentation product. The colitis is either ulcerative colitis or Crohn&#39;s disease. The pharmaceutical composition for colitis treatment or prevention comprises codonopsis lanceolata which includes Condonopsis lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as the active ingredient. The fermentation product is obtained by extracting of codonopsis lanceolata after fermentating or fermentating codonopsis lanceolata extracts. The fermentation is lactobacillus fermentation. A food composition for colitis improvement or prevention comprises Condonopsis lancemacide X, echinocystic acid 3-O-β-Dglucuronopyranoside: EAG, or saponin of echinocystic acid as the active ingredient.
PURPOSE:To facilitate the utilization of inspection data between the inspecting system and other system in its hospital, and also, to dispense with an external storage device of a large capacity. CONSTITUTION:Patients have their respective memory card, and a doctor writes in an inspection request item to its memory card. In a blood collecting room, personal inspection data is read out of the memory card, and its data is sent to an inspecting system 2, and also, an examined specimen bar-code label is issued. The examined specimen bar-code label is stuck to a blood collecting tube, and a patient&#39;s examined specimen is inserted therein. After the inspection is finished, a result of inspection is written in the memory card, and a medical prescription is also written in the memory card. In an accounting section, inspection performing information on that day is read out of the memory card and a bill is issued, and in a pharmacist&#39;s office, the medical prescription on that day is read out of its memory card and a medicine is prepared and delivered to the patient.
PURPOSE:To obtain the solid preparation containing a cycloheptenopyridine derivative having a proton pump-inhibiting action and useful as an antiulcer agent as an active ingredient, excellent in productivity and good in storage stability on the aspects of both the content and the appearance. CONSTITUTION:The solid preparation is prepared by compounding a compound of the formula (R is H, lower alkyl; R&lt;1&gt; is H, lower alkyl capable of being substituted; R&lt;2&gt; is H, halogen) or its salt, e.g. 9-(benzimidazol-2-yl)sulfinyl-4- methoxy-2,3-cycloheptenopyridine with magnesium oxide as a stabilizer, spray- dried lactose, granulated lactose, anhydrous lactose, calcium hydrogen phosphate or anhydrous calcium hydrogen phosphate as an excipient, and a starch derivative, preferably partially alpha-starch-containing starch or hydroxypropyl starch as a disintegrating agent, and subsequently granulating the mixture without using a granulation solvent. The stabilizer is preferably used in an amount of 0.3-3 pts.wt., especially 0.5-1,5 pts.wt., per pt. wt. of the compound of the formula, and the disintegrating agent is preferably used in an amount of 5-30%, especially 10-20%, based on the whole weight of the preparation.
The present invention provides a drug formulation comprising a hydrophobic drug, an oil phase and a surfactant and a dosage form. The drug formulation works to increase the bioavailability of hydrophobic drugs delivered to the gastro-intestinal tract (&#39;GI tract&#39;) of a desired subject. The drug formulation of the present invention is formulated as a self-emuslifying nanosuspension, which forms an emulsion in-situ upon introduction to an aqueous environment. The dosage form of the present invention may be formed using various different materials and may be configured to deliver the drug formulation of the present invention to the GI tract of a subject using any desired mechanism. A controlled release dosage form according to the present invention may be designed to deliver the drug formulation of the present invention at a desired rate over a desired period of time. If designed as a controlled release dosage form, the dosage form of the present invention may be an osmotic dosage form.
The present invention discloses a prescription of a &#39;dekang&#39; capsule for treating bone rheumatism, and a preparation method thereof. The capsule is mixed and prepared by extracting 20 Chinese herbal medicines of common monkshood mother root, prepared rhizome of rehmannia, etc. by addition of water, and fine materials processed by 10 Chinese herbal medicines of antler, centipede, etc. Decoction liquid of medicinal materials is extracted to concentrate paste; then the paste is processed into powder, and the powder and the fine powder of fine materials are mixed to prepare a capsule. The capsule has the functions of supplementing and strengthening pith, fortifying the waist and bones, relieving rigidity of muscle, activating collaterals, relieving inflammation and alleviating pains. The capsule is mainly used for treating cervical vertebra, lumbar vertebra, limbs joint hyperostosis and therapy of the waist, leg, neck and shoulder caused by various unknown reasons. The capsule has the advantages of outstanding curative effect, safety, small side effect and treatment of both manifestation and root cause of diseases.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for testing the susceptibility of a person to asthma.  &lt;P&gt;SOLUTION: The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a PTH (parathyroid hormone) aqueous solution stable to light and heat, especially, a prescription of an aqueous injectable solution.  &lt;P&gt;SOLUTION: This PTH aqueous solution is prepared by adding methionine and/or xylitol to an aqueous solution of PTH as an effective component. Favorably, pH of the aqueous solution is set at 3-5, and human-PTH(1-34) is used as the PTH. By this invention, the PTH is not dissolved at the point of use, but is preliminarily an aqueous solution of the PTH, and a PTH aqueous solution stable to heat and light is obtained. Therefore, deactivation during distribution and storage in a hospital can be prevented.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To obtain a dermal ointment free from oiliness when used, good in adhesivity and absorbability, thus useful as a pharmaceutical, cosmetic, etc., by incorporating active ingredient(s) in a base component comprising a mixture of acrylic and methacrylic copolymers, a lower alcohol and water. CONSTITUTION:The objective dermal ointment can be obtained by incorporating (A) a base component comprising (1) a film-forming agent, a mixture of acrylic and methacrylic copolymers (e.g. copolymers from at least two kinds of monomers selected from methacrylic acid, methyl methacrylate, ethyl acrylate, etc.). (2) a lower alcohol such as ethanol or isopropanol, and (3) water, with (B) active ingredient(s) such as antifungal agent, anti-inflammatory agent and/or hair grower. The production process is as follows: the above-mentioned film- forming agent, when the final agent is a solution is dissolved in the lower alcohol, and the resultant solution is incorporated with the active ingredient(s) and water followed by filling in an application container. Or, said film-forming agent, when the final agent is in the form of aerosol, is put into a pressure vessel, into which a propellant is then pressed. The amount of the water to be used is pref., such as to be &lt;=50wt.%, 5-50wt.% for solution; &lt;=20wt.% for aerosol agent.
The invention provides a culture cage for reducing disinfection time between chickens coming in and out of a cage. The culture cage comprises a frame, a cage and an egg conveying belt. The cage is of a cube structure formed by a front side board, a back side board, a bottom board, an upper side board and two side boards, wherein a drawing rail is fixed on the two sides of the bottom of a front face board. The drawing rail is slidably connected with the side boards. A limiting board is fixed on the upper portion of the front face board, and the limiting board is slidably connected with the upper side board. A hydraulic rod is fixed on the upper portion of the back side board, an output end of the hydraulic rod is provided with a mobile frame, and the lower surface of the mobile frame is provided with a plurality of ultraviolet lamps. Active ingredients of disinfecting drug in a medicine kettle of a liquid inlet pipe on the upper side board comprise angelica dahurica of 60-90 g, fructus cnidii of 60-90 g, gentiana macrophylla of 60-90 g, magnolia officinalis of 30-50 g, radix sileris of 30-50g, croton seed of 30-50 g, trichosanthes kirilowii maxim of 30-50 g, mint of 30-50 g , dragon&#39;s blood of 30-50 g, realgar of 15-30 g, zanthoxylum of 15-30 g, lycoperdon bovista of 15-30 g, equisetum hiemale stem of 15-30 g, mulberry leaf of 15-30 g, ginger of 15-30 g, dark plum of 15-30 g, chrysanthemum of 10-20 g, hydrargyrum oxydatum crudum of 15 g and 20% glutaraldehyde solution of 15 g. The culture cage is simple in structure, convenient to use and good in chicken coming out effect, chicken bodies and the vacated cage are disinfected synchronously when the chickens come out of the cage, and the pollution rate of pathogenic bacteria is reduced.
A method of predicting severity of multiple sclerosis (MS) in an animal in a vivarium is described. Animal activity data is collected at multiple times during the night. Sequential time regions of the night are identified as high-activity, activity-drop, or low-activity regions. Embodiments are described to quantify a drop, during the night, of an animal&#39;s activity level. These quantified activity-drop scalars for consecutive nights are accumulated in an animal health dataset. Then, an MS severity index function is applied to this dataset that, in response to the level of activity change and the speed of activity change, predicts or measures severity of MS in the animal. One embodiment quantifies an activity-drop by fitting straight-line curves through the data in the three nightly regions. Another embodiment uses a Fourier transform on a circle and a linear combination. Another embodiment compares areas under data curves in the regions. Animals may be housed in cages with other animals.
Some embodiments may provide a revolutionary cosmetic product to reduce the appearance of fine lines and/or wrinkles in a person&#39;s skin. In particular, an anti- wrinkle system may include a substantially flat silicone pad to be affixed to a person&#39;s skin  (e.g. , in an area around the person&#39;s chest, torso, neck, face, hands, backside, knees,  etc. ) and an activator substance to be applied between the silicone pad and the person&#39;s skin, including a humectant and a ferment in a suitable carrier. The activator substance might be associated with, for example, a gel, a cream, a lotion, a serum, and/or a mist. According to some embodiments, the anti-wrinkle medical grade silicone pad uses a mixture of ingredients harnessing them to represent a breakthrough, game-changing advance in the field of cosmetics that enhances the benefits of the anti-wrinkle medical grade silicone pad through additional wrinkle reduction beyond the anti-wrinkly pad alone.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an antidiabetic lowering blood cholesterol levels or blood total cholesterol or triglyceride levels.  &lt;P&gt;SOLUTION: This antidiabetic comprises Natto (fermented soybeans using Bacillus natto) kinase as the active ingredient. The Natto kinase is to be taken at 0.3-3 mg a day per adult. The antidiabetic, because of being capable of lowering blood cholesterol levels or blood total cholesterol(T-CHO) or triglyceride(TG) levels by oral administration, can be used as a drug for treating diabetes. The antidiabetic, because of being a food product extracted from Natto, has no side effects, and is highly safe.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
Natural interspecies antibodies (Ab) can be assigned to different animal species (e.g.mammals and birds) and have restricted reaction with a cellular antigen inherent to all animals and birds under conditions of cellular stress. Very high levels of Ab may indicate a tumour. Ab present initially destroy some tumours cell, causing release of Ag (&#39;reaction pattern in vertebrate cell antigens&#39;) which induce the immune system to produce more Ab. This corresponds to slow tumour growth and a good prognosis. USE/ADVANTAGE - Ab can be used in human or veterinary medicine for (1) preventing a pre-existing organ pattern; (2) for healing or preventing diseases associated with cell proliferation; (3) for diagnosing diseases of uncontrolled cell proliferation; or (4) for prepn. of highly purified, natural interspecies antigens (Ag) from solns. of biological materials. All mammals and birds produce functionally indistinguishable Ab.
PURPOSE:To provide the title inhibitor containing, as active ingredient, a fluorine contg. phenylalanine. CONSTITUTION:The objective inhibitor containing, as active ingredient, a compound of the formula (R&lt;1&gt; and R&lt;2&gt; are each H or protective group; R&lt;3&gt; is H, metal ion or cation; n is 1-5) or its salt, (e.g. p-fluorophenylalanine). The present compound has no significant inhibitory effect on carcinomatous proliferation, but gives strong carcinomatous invasion inhibitory activity, thus being effective as a metastasis inhibitor with small side effects. The compound of the formula can be synthesized, for example, from fluorobenzaldehyde through benzoyl aminofluorocinnamic acid.
The invention is directed to a newly discovered class of polynucleotide decoys that is capable of competitively inhibiting the binding of transcription factors to the X-box sequence. This binding is necessary for the expression of MHC-II genes. The invention is also directed to methods of preparing these polynucleotide decoys, and methods of use thereof. In particular, we have identified a class of polynucleotide decoys that mimic the X-Box of MHC-II and competitively bind the MHC-II transcription factor RF-X, resulting in the modulation of MHC-II antigen expression. Thus, the invention can be used to inhibit the expression of HLA molecules on the surface of donor cells or organs, in order to render them invisible to the host&#39;s immune system, or in methods of treating an individual with an autoimmune disease characterized by dysfunctional expression of an MHC class II antigen. Further, because of the role of RF-X in the expression of several viral proteins, the polynucleotide decoys of the invention can be used in methods of treating an individual infected with hepatitis B virus, or cytomegalovirus.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for diagnosing multiple sclerosis using objectively assessed biomarker levels and a method for predicting the development of attacks in a patient suffering from multiple sclerosis.  &lt;P&gt;SOLUTION: Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample. Disclosed is a method for diagnosing multiple sclerosis by comparing the levels of antibodies in a test sample from a subject to a control sample selected from the group consisting of one or more individuals who have multiple sclerosis symptoms and have a known multiple sclerosis status and one or more individuals who do not show multiple sclerosis symptoms. In one embodiment, the antibodies are anti-maltose IgM. In a specific embodiment, the levels of antibodies to a set of different glycans are measured by means of carbohydrate-chips.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The damage to hair during bleaching and dyeing with compounds yielding active oxygen, e.g. hydrogen peroxide, melamine perhydrate, percarbamide, perborates and persulphates, is reduced by treating it with a compound of the formula &lt;FORM:0990660/D1-D2/1&gt; in which X is -OH or -NH2, R1 is an aryl radical, an aliphatic radical with 1-5 carbon atoms or the radical &lt;FORM:0990660/D1-D2/2&gt; and R2 and R3 are hydrogen atoms or alkyl radicals with 1-5 carbon atoms, or a water-soluble salt thereof, e.g, the sodium, potassium, ammonium or ethanolamine salts.  The compound which may be applied to the hair before or during bleaching or dyeing as a solution, gel, cream, powder or paste, may also contain perfume oils, oxidation dyestuffs, thickeners, e.g. cellulose derivatives, polyvinyl pyrrolidone, polyacrylates, olginates and fatty alcohols, and anionic, cationic or nonionic wetting agents, e.g. fatty alcohol sulphates, alkyl sulphonates and condensation products of fatty alcohols with ethylene oxide in which the alkyl residues contain 12-18 carbon atoms, alkylbenzene sulphates and alkylpyridinium salts.  The treating composition preferably contains 0.01-10% by weight of the phosphorus-containing compound.
PURPOSE:To obtain an Al(OH)3.gel consisting of a specified compd. and useful in a field of application wherein said gel is used as an excellent antacid for acid in stomach, an acid adsorbing agent and a cation exchanger. CONSTITUTION:A soluble Al compd. (e.g. AlCl3) consisting of water-soluble and/or lower alcohol soluble salt, and a soluble compd. of a source for supplying carbonic ion (e.g. Na2CO3) are brought into reaction at pH6-9.5 at 20-50 deg.C so that molar ratio of CO2/Al in the Al(OH)3.gel obtained by the reaction become &gt;=0.1. Then, the Al(OH)3.gel contg. &lt;=2wt.% alkali metal and expressed in inequality I [wherein, M is alkali metal such as Na, K; x1-3 is the relation expressed in inequalities II-VII, respectively; (y) is positive number in the formula VIII, (m) is positive number in inequality IX] is formed by ion- exchanging the alkali metal contained in the obtained compd. with Ca, or Ca and Mg. The tablet of antacid, etc., is prepared by mixing said Al(OH)3.gel with a desired ecipient, etc., if necessary, and then is utilized for adjusting acidity for acid in stomach by dosing at the rate of 2-5g/day.
Attenuated strains of Listeriosis monocitogenes deposited in &#34;NBPMKK&#34; under numbers 251 and 252 are cultivated on meat-peptone bouillon in a fermenter, the bouillon containing 8-20 g/l glucose. Cultivation is at 35-37 DEG C and pH from 7 to 7.6, with air passed through preferably at 3-5 l/min, and a stirrer operated at 300 to 1000 r.p.m. The amount of innoculum is from 1:20 to 1:100 of the working volume of the fermenter. After termination of the cultivation, depending on the density of the biomass obtained, the latter is diluted with protective medium and then it may be homogenised and lyophilised. A biomass having a density of 12 milliard/ cm&lt;3&gt; living bacterial cells may be obtained. For lyophilising of the vaccine, a protective medium containing 2 to 17% by weight sodium glutamate, 5 to 20% saccharose and 0.5 to 5% by weight denatured gelatine is presently used.
The invention discloses a preparation method of dragon&#39;s blood and Meles meles ulcer oil. The dragon&#39;s blood and Meles meles ulcer oil is mainly prepared from dragon&#39;s blood, bee wax and Meles meles fat. The dragon&#39;s blood and Meles meles ulcer oil is used for treating various ulcers such as gastric ulcers, duodenal ulcers, colonic ulcers, burns and scalds, diabetic feet, bedsores and haemorrhoids, can be taken orally or applied externally or used in an oral taking and external applying combined mode, and is significant in treatment effect. The ulcer oil can effectively improve the body immunity, promote proliferation and migration of intradermal cells and in-vitro lumen formation, increase the blood flow of the ulcer part, regulate metabolism, induce hypodermal cells, fibrocyte, blood capillaries, nerve endings and muscles to generate a series of tissue repair, accelerate regeneration of damaged cells and ensure complete coverage of superficial cells. The ulcer oil is prepared from fatty acid extremely similar to fat of the human skin and has very strong permeability, oleic acid can form cracks by perturbing the cuticle and the lipid bilayer to promote permeation, and oleic acid and linoleic acid can promote total closure of wounds and restrain generation of nitric oxide in wound tissue. The effective rate of treatment on peptic ulcers such as gastric ulcers and intestinal ulcers reaches 99%.